Loading patent…
AssigneeThe Trustees of the University of Pennsylvania
InventorsYangbing Zhao, Carl H. June, Xiaojun Liu
Estimating the term…
The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.
A method for enhancing T cell antitumor activity in a subject in need thereof, the method comprising parenterally administering to the subject a composition comprising modified CAR T cells comprising a nucleic acid sequence encoding a switch molecule and a nucleic acid sequence encoding a CAR comprising an antigen binding domain that targets a tumor antigen, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain;
A method for enhancing T cell antitumor activity in a subject in need thereof, the method comprising parenterally administering to the subject a composition comprising modified T cells comprising a nucleic acid sequence encoding a switch molecule and a nucleic acid sequence encoding a chimeric antigen receptor (CAR) that targets a tumor antigen,
Dependencies are inferred from the claim text.